Lung Isolation Techniques in Patients With Early-Stage or Long-Term Tracheostomy: A Case Series Report of 70 Cases and Recommendations

2019 ◽  
Vol 33 (2) ◽  
pp. 433-439 ◽  
Author(s):  
Javier H. Campos ◽  
Eli D. Musselman ◽  
Satoshi Hanada ◽  
Kenichi Ueda
Author(s):  
Miguel A. Quiroz-Reyes ◽  
Erick A. Quiroz-Gonzalez ◽  
Jorge Morales-Navarro ◽  
Felipe Esparza-Correa ◽  
Jorge E. Aceves-Velazquez ◽  
...  

Background: There is abundant and even confusing information in the available literature concerning the role of internal limiting membrane (ILM) removal in macular conditions secondary to non-complicated macula-off rhegmatogenous retinal detachment (RRD) repair. This retrospective, multicenter, long-term study aimed to analyze the incidence of epiretinal membrane (ERM) proliferation and other surgical complications and to compare the postoperative microstructural and multimodal imaging findings and correlate them with the final postoperative best-corrected visual acuity (BCVA) in selected eyes.


Oncotarget ◽  
2017 ◽  
Vol 8 (14) ◽  
pp. 23130-23141 ◽  
Author(s):  
Xu-Rui Jin ◽  
Lu-Yao Zhu ◽  
Kai Qian ◽  
Yong-Geng Feng ◽  
Jing-Hai Zhou ◽  
...  

2015 ◽  
Vol 19 (6) ◽  
pp. 561-569 ◽  
Author(s):  
Marc Bourcier ◽  
Kim Alexander Papp ◽  
Wayne P. Gulliver ◽  
Yves Poulin ◽  
Kirk Barber ◽  
...  

Background: Currently, etanercept (ETN) safety and efficacy in patients with moderate to severe plaque psoriasis (PsO) has been reported up to 5 years. Objective: To present a case series of PsO patients receiving continuous ETN therapy for 7 or more years. Methods: Physicians collected data retrospectively from 52 patient charts from 5 centres across Canada. Results: Patients in this case series had PsO an average of 31.5 years. Nearly half of patients also had psoriatic arthritis (24/52). All patients demonstrated sustained improvement in Psoriasis Area and Severity Index (PASI) and percentage of affected body surface area (BSA) following ETN treatment. Of the 52 patients, 33 have been receiving ETN for 10 years or more. Conclusion: The clinical experience described in this case series report suggests maintenance of ETN efficacy in PsO patients who receive therapy for 7 years or more and indicates that patients can be successfully managed with long-term ETN therapy.


2013 ◽  
Vol 271 (7) ◽  
pp. 1851-1856 ◽  
Author(s):  
B. K. Mukara ◽  
P. Munyarugamba ◽  
S. Dazert ◽  
J. Löhler

Dermatology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Jurr Boer

<b><i>Background:</i></b> Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT. <b><i>Objectives:</i></b> To evaluate the long-term efficacy of RT in early-stage HS. <b><i>Methods:</i></b> A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated. <b><i>Results:</i></b> The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32–52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey. <b><i>Conclusions:</i></b> RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.


2012 ◽  
Vol 38 (10) ◽  
pp. 1435-1442 ◽  
Author(s):  
Mohamed I. Fayad ◽  
Paul J. Ashkenaz ◽  
Bradford R. Johnson

Sign in / Sign up

Export Citation Format

Share Document